Alatab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17–30 (2020).
Hoivik, M. L. et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm. Bowel Dis. 18, 1540–1549 (2012).
Citi, S. Intestinal barriers protect against disease. Science 359, 1097–1098 (2018).
Turner, J. R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9, 799–809 (2009).
Chu, H. et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 352, 1116–1120 (2016).
Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
Plichta, D. R., Graham, D. B., Subramanian, S. & Xavier, R. J. Therapeutic opportunities in inflammatory bowel disease: mechanistic dissection of host-microbiome relationships. Cell 178, 1041–1056 (2019).
Jostins, L. et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
Grisham, M. B. Oxidants and free radicals in inflammatory bowel disease. Lancet 344, 859–861 (1994).
Dickinson, B. C. & Chang, C. J. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat. Chem. Biol. 7, 504–511 (2011).
Lee, Y. et al. Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier microbiome and immune responses in colitis. Nat. Mater. 19, 118–126 (2020).
Scott, B. M. et al. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease. Nat. Med. 27, 1212–1222 (2021).
Bernstein, C. N. et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm. Bowel Dis. 16, 112–124 (2010).
Lautenschläger, C., Schmidt, C., Fischer, D. & Stallmach, A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv. Drug Deliv. Rev. 71, 58–76 (2014).
Cader, M. Z. & Kaser, A. Finding the right target for drug-resistant inflammatory bowel disease. Nat. Med. 27, 1870–1871 (2021).
Suez, J., Zmora, N., Segal, E. & Elinav, E. The pros, cons, and many unknowns of probiotics. Nat. Med. 25, 716–729 (2019).
Motta, J.-P. et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med. 4, 158ra144–158ra144 (2012).
Brioukhanov, A. L. & Netrusov, A. I. Aerotolerance of strictly anaerobic microorganisms and factors of defense against oxidative stress: a review. Appl. Biochem. Microbiol. 43, 567–582 (2007).
McCord, J. M., Keele, B. B. Jr. & Fridovich, I. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. Proc. Natl Acad. Sci. USA 68, 1024–1027 (1971).
Imlay, J. A. How oxygen damages microbes: oxygen tolerance and obligate anaerobiosis. Adv. Microb. Physiol. 46, 111–153 (2002).
Tally, F. P., Goldin, B. R., Jacobus, N. V. & Gorbach, S. L. Superoxide dismutase in anaerobic bacteria of clinical significance. Infect. Immun. 16, 20–25 (1977).
Huang, Y., Ren, J. & Qu, X. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications. Chem. Rev. 119, 4357–4412 (2019).
Jiao, L. et al. When nanozymes meet single-atom catalysis. Angew. Chem. Int. Ed. 59, 2565–2576 (2020).
Cao, F. et al. An enzyme-mimicking single-atom catalyst as an efficient multiple reactive oxygen and nitrogen species scavenger for sepsis management. Angew. Chem. Int. Ed. 32, 5108–5115 (2020).
Zhang, C. et al. Colonization and probiotic function of Bifidobacterium longum. J. Funct. Foods 53, 157–165 (2019).
Chen, Y. et al. Isolated single iron atoms anchored on N-doped porous carbon as an efficient electrocatalyst for the oxygen reduction reaction. Angew. Chem. Int. Ed. 56, 6937–6941 (2017).
Zhang, H. et al. Single atomic iron catalysts for oxygen reduction in acidic media: particle size control and thermal activation. J. Am. Chem. Soc. 139, 14143–14149 (2017).
Pan, Y. et al. Regulating the coordination structure of single-atom Fe-NxCy catalytic sites for benzene oxidation. Nat. Commun. 10, 4290 (2019).
Bull, S. D. et al. Exploiting the reversible covalent bonding of boronic acids: recognition, sensing, and assembly. Acc. Chem. Res. 46, 312–326 (2013).
Geng, W. et al. Click reaction for reversible encapsulation of single yeast cells. ACS Nano 13, 14459–14467 (2019).
Bron, P. A., van Baarlen, P. & Kleerebezem, M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 10, 66–78 (2012).
Hua, S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract-influence of physiological, pathophysiological and pharmaceutical factors. Front. Pharmacol. 11, 524 (2020).
Stillhart, C. et al. Impact of gastrointestinal physiology on drug absorption in special populations––an UNGAP review. Eur. J. Pharm. Sci. 147, 105280 (2020).
Pawar, V. K. et al. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv. 18, 97–110 (2011).
Wirtz, S., Neufert, C., Weigmann, B. & Neurath, M. F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541–546 (2007).
Liu, Y. et al. Integrated cascade nanozyme catalyzes in vivo ROS scavenging for anti-inflammatory therapy. Sci. Adv. 6, eabb2695 (2020).
Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183–1189 (2009).
Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012).
Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55, 205–211 (2006).
Wright, E. K. et al. Recent advances in characterizing the gastrointestinal microbiome in Crohn’s disease: a systematic review. Inflamm. Bowel Dis. 21, 1219–1228 (2015).
Shang, L. et al. Core altered microorganisms in colitis mouse model: a comprehensive time-point and fecal microbiota transplantation analysis. Antibiotics 10, 643 (2021).
Salem, F. et al. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: similarities and differences. United Eur. Gastroenterol. J. 7, 1008–1032 (2019).
Baldelli, V., Scaldaferri, F., Putignani, L. & Del Chierico, F. The role of enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases. Microorganisms 9, 697 (2021).
Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299–306 (2012).
Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292–298 (2012).
Ziegler, A., Gonzalez, L. & Blikslager, A. Large animal models: the key to translational discovery in digestive disease research. Cell. Mol. Gastroenterol. Hepatol. 2, 716–724 (2016).
National Institute of Diabetes and Digestive and Kidney Diseases. Opportunities and Challenges in Digestive Diseases Research: Recommendations of the National Commission on Digestive Diseases. NIH Publication No. 08–6514 (National Institutes of Health, 2009).
Chandra, L. et al. Derivation of adult canine intestinal organoids for translational research in gastroenterology. BMC Biol. 17, 33 (2019).
Schaefer, K., Rensing, S., Hillen, H., Burkhardt, J. E. & Germann, P. G. Is science the only driver in species selection? An internal study to evaluate compound requirements in the minipig compared to the dog in preclinical studies. Toxicol. Pathol. 44, 474–479 (2016).
Mehrabani, D. et al. The healing effect of Teucrium polium in acetic acid-induced ulcerative colitis in the dog as an animal model. Middle East J. Dig. Dis. 4, 40–47 (2012).
Ballal, S. A. et al. Host lysozyme-mediated lysis of Lactococcus lactis facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons. Proc. Natl Acad. Sci. USA 112, 7803–7808 (2015).
Han, W. et al. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm. Bowel Dis. 12, 1044–1052 (2006).
de Moreno de LeBlanc, A. et al. Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice. J. Med. Microbiol. 57, 100–105 (2008).
Liu, M. et al. Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis. Int. Immunopharmacol. 57, 25–32 (2018).
LeBlanc, J. G. et al. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn’s disease in mice. J. Biotechnol. 151, 287–293 (2011).
Zhao, S. et al. An orally administered CeO2@montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy. Adv. Funct. Mater. 30, 2004692 (2020).
Cheng, C., Zhao, S., Cheng, Y., Liu, Y. & Wei, H. Design of nanozymes for inflammatory bowel disease therapy. Sci. China Life Sci. 64, 1368–1371 (2021).
Wei, H. & Wang, E. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes. Chem. Soc. Rev. 42, 6060–6093 (2013).
Cheng, C. et al. Multifunctional nanozyme hydrogel with mucosal healing activity for single-dose ulcerative colitis therapy. Bioconjugate Chem. 33, 248–259 (2022).
Lin, S. et al. Mucosal immunity-mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer’s patches. Sci. Adv. 7, eabf0677 (2021).
Anselmo, A. C., McHugh, K. J., Webster, J., Langer, R. & Jaklenec, A. Layer-by-layer encapsulation of probiotics for delivery to the microbiome. Adv. Mater. 28, 9486–9490 (2016).
Zheng, D. W. et al. Prebiotics‐encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Adv. Mater. 32, 2004529 (2020).
Centurion, F. et al. Nanoencapsulation for probiotic delivery. ACS Nano 15, 18653–18660 (2021).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: https://www.nature.com/articles/s41565-023-01346-x